NMRA Neumora Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-08-24
Why NMRA matters now
Neumora Therapeutics, Inc. Common Stock (NMRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.53 with -6.44% on the session and $282.6M in market capitalization; recent performance reads 1-month -9.58% and YTD -15.64%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-53.5M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -69.1%.
The latest indexable market news headline is "Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Ho Maykin filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.84
P/S
0.00
EV/EBITDA
-0.61
DCF Value
$1.10
FCF Yield
-69.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-181.7%
ROA
-144.5%
ROIC
-179.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-53.5M | $-0.30 |
| Q4 2025 | $0.00 | $-59.5M | $-0.35 |
| FY 2025 | $0.00 | $-236.9M | $-1.45 |
| Q3 2025 | $0.00 | $-56.8M | $-0.35 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$4.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.76
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.